Sequence: YGRKKRRQRRR
| Experiment Id | EXP001693 |
|---|---|
| Paper | Liquid Crystalline Nanodispersions Functionalized with Cell-Penetrating Peptides for Topical Deliver |
| Peptide | TAT (HIV-1 Tat 47–57) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.1 mM (in nanodispersion) |
| Rna Concentration | 10 µM siRNA TNF-α in topical formulation (100 µL applied) |
| Mixing Ratio | CPP pre-complexed with siRNA 30 min, then added to nanodispersion |
| Formulation Format | Topical hexagonal liquid crystalline nanodispersion (MO:OA:PEI) functionalized with TAT |
| Formulation Components | MO:OA:PEI:aqueous phase (8:2:1:89, w/w/w/w) + Poloxamer 407 (1.5%) + TAT + siRNA TNF-α |
| Size Nm | 310.00 |
| Zeta Mv | 12.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Hairless mice (HRS/J); TPA-induced cutaneous inflammation model (psoriasis-like) |
| Administration Route | Topical (100 µL over 2 cm² on back skin); TPA applied 1 h later; analysis at 6 h post-TPA |
| Output Type | in vivo functional knockdown (protein level) |
| Output Value | Significant reduction of skin TNF-α levels (ELISA) vs controls; TAT-functionalized nanodispersion outperformed non-functionalized nanodispersion and PEI solution controls. |
| Output Units | |
| Output Notes | In vivo skin penetration also assessed with FAM-siRNA (12 h) showing deeper penetration with TAT-functionalized nanodispersion. |
| Toxicity Notes | No significant skin irritation by H&E (no epidermal thickening/inflammatory infiltration) for MO:OA:PEI ± TAT. |
| Curation Notes |